The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, ...

The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

The late-stage results come in advance of pivotal data that Ionis expects to provide for its antisense oligonucleotide ...

In an interview on Friday, FDA Commissioner Marty Makary threw his weight behind psychedelic therapies, noting that patients ...

The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...